Perspectives in Medicinal Chemistry

Revisiting the Monoamine Hypothesis of Depression: A New Perspective

Joel S. Goldberg¹, Clifton E. Bell Jr.² and David A. Pollard²

¹Durham Veterans Affairs Medical Center, Duke University School of Medicine, Durham, North Carolina, USA. ²Department of Chemistry, Winston-Salem State University, Winston-Salem, North Carolina, USA.

ABSTRACT: As the incidence of depression increases, depression continues to inflict additional suffering to individuals and societies and better therapies are needed. Based on magnetic resonance spectroscopy and laboratory findings, gamma aminobutyric acid (GABA) may be intimately involved in the pathophysiology of depression. The isoelectric point of GABA (pI = 7.3) closely approximates the pH of cerebral spinal fluid (CSF). This may not be a trivial observation as it may explain preliminary spectrophotometric, enzymatic, and HPLC data that monoamine oxidase (MAO) deaminates GABA. Although MAO is known to deaminate substrates such as catecholamines, indoleamines, and long chain aliphatic amines all of which contain a lipophilic moiety, there is very good evidence to predict that low concentration of a lipophilic microspecies of GABA is present when GABA pI = pH as in the CSF. Inhibiting deamination of this microspecies of GABA could explain the well-established successful treatment of refractory depression with MAO inhibitors (MAOI) when other antidepressants that target exclusively levels of monoamines fail. If further experimental work can confirm these preliminary findings, physicians may consider revisiting the use of MAOI for the treatment of non-intractable depression because the potential benefits of increasing GABA as well as the monoamines may outweigh the risks associated with MAOI therapy.

KEYWORDS: monoamine oxidase, depression, GABA

CITATION: Goldberg et al. Revisiting the Monoamine Hypothesis of Depression: A New Perspective. Perspectives in Medicinal Chemistry 2014:6 1–8
doi: 10.4137/PMc.S11375.

ACADEMIC EDITOR: Yitzhak Tor, Editor in Chief

TYPE: Perspective

FUNDING: Author(s) disclose no funding sources.

COMPETING INTERESTS: Author(s) disclose no potential conflicts of interest.

COPYRIGHT: © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

CORRESPONDENCE: joel.goldberg2@va.gov

Introduction

In the 1950s, the amine hypothesis of depression was proposed after it was observed that patients treated for hypertension with reserpine developed depression.¹ Since that time, pharmacologic therapy for treatment of depression has focused on increasing concentrations of brain monoamines, namely nor-epinephrine, serotonin, and dopamine.

These neurotransmitters are present at an average concentration of 10⁻⁹ mol/kg vs. 10⁻⁶ mol/kg for gamma aminobutyric acid (GABA) and glutamate.² With such low concentrations, the monoamines may serve as fine tuners for the predominant GABA/glutamate neurotransmitters.

Evidence that GABA is Important in the Diagnosis and Possible Treatment of Depression

1. The concept that deficiencies of GABA may contribute to depression is not new and has been proposed in the literature.²,³ GABA has been shown to release monoamines in animal models.⁴
2. Magnetic resonance spectroscopy of selected voxels of brain images particularly in the occipital, frontal, and anterior cingulate cortex clearly supports the concept that tissue GABA is decreased in depression.³,⁵,⁶
3. In animal models, phenelzine, an inhibitor and substrate of monoamine oxidase (MAO), elevates cortical GABA levels.⁷,⁸ This effect is other than or in addition to inhibition of GABA transaminase (GABA-T).⁷,⁸
4. Finally, this paper proposes that MAO deamination of GABA may occur as a secondary pathway for its catabolism. MAO binds preferentially to substrates that contain lipophilic moieties such as aromatic groups or long straight chain aliphatic amines.⁹ Because MAO catalyzes deamination of some aliphatic amines, it seems quite plausible that it could catalyze deamination of a lipophilic form of GABA.⁹,¹⁰ Deamination of GABA by MAO may
occur in vivo because the isoelectric point (pI) of GABA (7.3) is very close to the pH of human cerebral spinal fluid (CSF) (7.28–7.32). This may not be a trivial observation as the non-charged microspecies of GABA in the CSF may be very lipophilic based on reported studies of niflumic acid in an environment where pI = pH. If this relationship is true for GABA, the non-charged lipophilic microspecies may be a suitable substrate for MAO. Figure 1 illustrates the generic of this equilibrium. Thus, deamination of GABA may not only be catalyzed by GABA-T (Fig. 2) but also in small quantities by MAO. This could account for the clinical observation that MAO inhibitors (MAOI) are effective antidepressant medications for the most refractory depressions especially when selective serotonin reuptake inhibitors (SSRI) and tricyclic antidepressants (TCA) have failed.

Methods
Preliminary experimental data to support deamination of GABA by MAO.

1. Spectrophotometric evidence of GABA deamination by MAO-A

Determination of an absorption (Ab) curve for GABA in phosphate buffered saline (PBS). The deuterium lamp output on a Pharmacia Ultrospec III spectrophotometer was stabilized after 45 minutes. Solutions of PBS and PBS with GABA (total volume 1.04 mL) at concentrations of $10^{-2}$, $10^{-3}$, $10^{-4}$, and $10^{-5}$ mmol/mL were added to quartz cuvettes. The cuvettes were gently tapped to displace any bubbles. Ab data were recorded at 5-nm intervals from 200 to 800 nm, and reference was set at each new wavelength using the PBS blank. Peak Ab at 205 nm was observed in the $10^{-2}$ and $10^{-3}$ solutions (Figs. 3 and 4). This far UV Ab peak approximated a published UV Ab of GABA on thin layer chromatography.

Spectrophotometric deamination of GABA by MAO-A. After incubation of GABA and PBS controls at 37 °C, 5 and 10 µL of MAO-A (Sigma product number M7316, 5 mg protein/mL) was added to the cuvettes except for the PBS blank, and the samples were incubated for an additional 30 minutes at 37 °C. Ab measured at 205 nm and $\Delta$Ab (Abfinal – Abinitial) corrected for MAO-A Ab (Tables 1 and 2).

2. GABA reacts with MAO-A to produce ammonia

GABA incubated with MAO-A produces ammonia. Samples of PBS, PBS + MAO-A, PBS + MAO-A + GABA, and PBS + MAO-A + serotonin were assayed for ammonia. A total of 5 mL of each sample was incubated at 35 °C for two hours and agitated every 30 minutes. The samples were frozen at −10 °C overnight and then defrosted, placed in lithium heparin tubes, and analyzed for ammonia using a Siemens Dimension Vista Analyzer in the clinical chemistry laboratory of the Durham Veterans Affairs Medical Center (Table 3).

---

**Figure 1.** Near the isoelectric point of an amino acid such as GABA, a very lipophilic form exists.

**Note:** en.wikipedia.org/wiki/Zwitterion, Zwitterion – Wikipedia, the free encyclopedia.

**Figure 2.** GABA metabolism. Revised with permission from Dr. Matthias C. Lu. Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago College of Pharmacy.

**Figure 3.** UV Ab of $10^{-3}$ M GABA.

**Figure 4.** UV Ab of $10^{-2}$ M GABA.
Monoamine hypothesis depression

### Table 1. Decrease in GABA absorption with 5 µL MAO-A.

| SAMPLE | INITIAL ABSORPTION | INITIAL ABSORPTION CORRECTED | FINAL ABSORPTION | ∆ ABSORPTION |
|--------|--------------------|-------------------------------|-----------------|--------------|
| PBS    | −0.37              | 0.25                          | 0.29            | 0.29         |
| 10^{−2}M GABA | 0.83              | 1.27                          | 0.98            | −0.29        |
| 10^{−3}M GABA | 0.08              | 0.37                          | 0.27            | −0.10        |
| 10^{−4}M GABA | −0.01             | 0.28                          | 0.20            | −0.08        |

3. HPLC supports that MAO deaminates GABA at pH 7.4

Concentrations of GABA 10^{−2}–10^{−6} M were prepared in PBS. Solutions of 10 mL GABA were incubated with 50 µL of MAO-A or MAO-B (Sigma, St. Louis, MO) at 37 °C for two hours agitated at 30-minute intervals. The solutions were centrifuged for 15 minutes at 2,000 rpm, and 1 mL of the top layer of each tube was stored at −10 °C until ready for assay. The HPLC conditions were as follows: flow rate −0.400 mL/minute, eluent − 80:20:0.1% (H₂O:CH₃CN:TFA), run time −5 minutes, detector − UV (205 nm), and temperature − 30 °C.

The chromatograms show products of the reaction of GABA with MAO. These products were not detectable at lower concentrations of GABA with the same enzyme concentration, and therefore there was no interference with the enzyme (Figs. 5–9).

### Results

The preliminary data support the hypothesis that in vitro at higher than physiologic concentrations, MAO deaminates GABA. If these findings are confirmed and found to occur in vivo, they could have clinical significance. Experienced psychiatrists have long known that MAOI are preferred agents for refractory depression, and these data present a possible mechanism.

Potential flaws in the concepts were as follows:

A. The data are preliminary without statistics. However preliminary, three distinct analytic methods support the hypothesis.

B. Depression is a disease with many causes. It is unlikely that correcting a deficiency of brain monoamines or GABA will be a panacea. Supporting this statement is the clinical observation that psychotherapy combined with pharmacologic therapy produces the best treatment outcome for depression.\(^{16}\)

### Discussion

If further experimental work confirms that brain MAO deaminates GABA that is deficient in depression, the under use of MAOI for the treatment of depression may need to be reexamined. Also the use of serotonin and norepinephrine reuptake inhibitors as first-line agents may need to be reevaluated. The reluctance to use MAOI except in patients with refractory depression may be a cause of therapeutic failures. Reviewing the literature on MAOI therapy, the risks of hypertensive crisis from food containing tyramine or postural hypotension from false neurotransmitters are quite small, but can be catastrophic.\(^{37,18}\) The former can be avoided through proper diet and the latter through hydration, compressive stockings, and if needed mineralocorticoid supplementation. Better physician and patient education could decrease the rare complications of serotonin toxicity from use of MAOI with some opioids or serotonin reuptake inhibitors.\(^{19,20}\) In patients suffering, very refractory depression treatment with MAOI combined with a stimulant such as methylphenidate or dextroamphetamine has been successful and may defer the use of electroshock therapy.\(^{17,21}\)

### Conclusion

Depression is a ubiquitous illness found in all races, cultures, and socioeconomic groups. The global burden of disease caused by depression is huge and increasing. Probably, GABA and the monoamines are involved in the cause of depression. The pH of CSF closely approximates the isoelectric point of GABA (pH = pI), and there is very good evidence to support that small quantities of very lipophilic GABA microspecies exist in the CSF. Preliminary data suggest that deamination of non-physiologic concentrations of GABA is catalyzed by MAO. Even though the quantities of lipophilic GABA and
deamination products may be extremely small, in the milieu of the central nervous system, very small changes in GABA could have clinical significance. If the concepts presented in this paper can be proven, even with the known autonomic risks, treatment with MAOI may be considered earlier in the pharmacologic treatment of depression.

Acknowledgments
The authors would like to especially thank Kathy Gage and Julie Rosato of Duke University for editorial assistance.

Table 3. Incubation of $10^{-3}$ M GABA with MAO-A produces ammonia.

| SAMPLE | MAO-A | GABA mol/L | SEROTONIN mol/L | AMMONIA µmol/L |
|--------|-------|-------------|----------------|----------------|
| #1. PBS | –     | –           | –              | <25            |
| #2. PBS | 20 µL | –           | –              | <25            |
| #3. PBS | 50 µL | $10^{-2}$   | –              | <25            |
| #4. PBS | 50 µL | $10^{-1}$   | –              | 302            |
| #5. PBS | 20 µL | –           | $10^{-2}$      | 185            |

Figure 5. $10^{-2}$ M GABA in PBS.
The authors would also like to thank Thomas Van de Ven, MD, PhD, and John Toffaletti, PhD, for spectroscopy advice and David Lindsay, MD, and Jean Tetterton, NP, for taking time to review the manuscript.

**Author Contributions**
Conceived and designed the experiments: JSG. Analyzed the data: JSG, CEB, DAP. Wrote the first draft of the manuscript: JSG. Contributed to the writing of the manuscript: JSG, CEB, DAP. Agree with manuscript results and conclusions: JSG, CEB, DAP. Jointly developed the structure and arguments for the paper: JSG. Made critical revisions and approved final version: JSG, CEB, DAP. All authors reviewed and approved of the final manuscript.

**Figure 6.** $10^{-2}$ M GABA in PBS with MAO-A.

**Peak table**

| Peak # | Name      | Ret time | Area   | Height |
|--------|-----------|----------|--------|--------|
| 1      | PBS buffer| 1.444    | 1346768| 173353 |
| 2      | GABA      | 2.961    | 22389  | 2623   |
| 3      | GABA      | 3.300    | 793    | 114    |
| 4      | GABA      | 3.452    | 1713   | 169    |
| 5      | GABA      | 3.717    | 473    | 50     |
| 6      | GABA      | 4.106    | 1497   | 133    |
| **Total** |           |          |        | 1373632 |

**DISCLOSURES AND ETHICS**
As a requirement of publication the authors have provided signed confirmation of their compliance with ethical and legal obligations including but not limited to compliance with ICMJE authorship and competing interests guidelines, that the article is neither under consideration for publication nor published elsewhere, of their compliance with legal and ethical guidelines concerning human and animal research participants.
REFERENCES

1. Freis ED. Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med. 1954;251(25):1006–8.
2. Kugaya A, Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr. 2005;10(10):808–19.
3. Sanacora G, Guerguieva R, Epperson CN, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004;61(7):705–13.
4. Rattan AK, Dhatt RK, Mangat HK. Qualitative and quantitative changes in monoamine oxidase activity after acute third ventricle treatment of GABA, muscimol, and picrotoxin in rat. Gegenbaurs Morphol Jahrb. 1989;135(2):357–65.
5. Price RB, Shungu DC, Mao X, et al. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry. 2009;65(9):792–800.
6. Hasler G, van der Veen JW, Tzounis T, et al. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007;64(2):193–200.
7. Todd KG, Baker GB. GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (−)-deprenyl and clorgyline. J Affect Disord. 1995;35(3):125–9.

Figure 7. 10^{-2} M GABA in PBS with MAO-B.
Monoamine hypothesis depression

8. Todd KG, Baker GB. Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: a comparison with vigabatrin. *J Pharm Pharmacol.* 2008;11(2):14s–21s.

9. Yu PH. Deamination of aliphatic amines of different chain lengths by rat liver monoamine oxidase A and B. *J Pharm Pharmacol.* 1989;41(3):205–8.

10. Tenne M, Youdim MB, Ulitzur S, Finberg JP. Deamination of aliphatic amines by monoamine oxidase A and B studied using a bioluminescence technique. *J Neurochem.* 1985;44(5):1373–7.

11. Greenstein JP, Winitz M. *Chemistry of the Amino Acids.* Vol 1. New York: John Wiley & Sons; 1961.

12. Goldberg JS. Selected gamma aminobutyric acid (GABA) esters may provide analgesia for some central pain conditions. *Perspect Med Chem.* 2010;4:23–31.

13. Mazak K, Kokosi J, Noszal B. Lipophilicity of zwitterions and related species: a new insight. *Eur J Pharm Sci.* 2011;44(1–2):68–73.

14. Frieling H, Bleich S. Tranylcypromine: new perspectives on an “old” drug. *Eur Arch Psychiatry Clin Neurosci.* 2006;256(5):268–73.

15. Saravana Babu C, Kesavanarayanan KS, Kalavani P, Ranju V, Ramanathan M. A simple densitometric method for the quantification of inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in rat brain tissue. *Chromatogr Res Int.* 2011:1–5.

16. Cuijpers P, van Straten A, Warmerdam L, Andersson G. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. *Depress Anxiety.* 2009;26(3):279–88.

17. Feinberg SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. *J Clin Psychiatry.* 2004;65(11):1520–4.

**Figure 8.** $10^{-4}$ M GABA in PBS with MAO-A.
18. Flockhart DA. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update. *J Clin Psychiatry*. 2012;73(suppl 1):17–24.

19. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. *Br J Anaesth*. 2005;95(4):434–41.

20. Keltner N, Harris CP. Serotonin syndrome: a case of fatal SSRI/MAOI interaction. *Perspect Psychiatr Care*. 1994;30(4):26–31.

21. Fawcett J, Kravitz HM, Zajecka JM, Schaff MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. *J Clin Psychopharmacol*. 1993;11(2):127–132.

**Figure 9.** $10^{-4}$ M GABA in PBS with MAO-B.